Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256589 | 0.88 | GRIN2B (0.39) | HTR2AHTR2CHTR2BKMOGRIN2B | |
| SCHEMBL7253155 | 0.84 | GRIN2B (0.41) | HTR2AHTR2CHTR2BKMOGRIN2B | |
| SCHEMBL7256625 | 0.82 | MCHR1 (0.46) | HTR2AHTR2CHTR2BKMOGRIN2B | |
| SCHEMBL7253398 | 0.79 | HTR1D (0.48) | HTR2AHTR2CHTR2BKMOBRD4 | |
| SCHEMBL7252996 | 0.76 | HTR1D (0.52) | BRD4HTR1D | |
| SCHEMBL7252961 | 0.76 | BRD4 (0.36) | HTR2AHTR2CHTR2BKMOBRD4 | |
| SCHEMBL7572923 | 0.76 | HTR2A (0.44) | HTR2AHTR2CHTR2BKMOHTR1D | |
| SCHEMBL7253683 | 0.76 | KMO (0.57) | HTR2AHTR2CHTR2BKMOSMN1; SMN2 | |
| SCHEMBL7253254 | 0.73 | MKNK1 (0.40) | BRD4SMN1; SMN2PKM | |
| SCHEMBL7253556 | 0.72 | HTR1D (0.46) | HTR2AHTR2CHTR2BKMOBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | claimed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | claimed |
| US-6635639-B2 | Treatment or diagnosis of central nervous system conditions | NPS ALLELIX CORP. (CA) | 2003-10-21 | — | — | US | disclosed |
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | NPS ALLEXLIX CORP. | 2002-11-14 | — | — | US | disclosed |
| US-6380242-B1 | FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS | NPS ALLELIX CORP. (CA) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169322-A1 | Use of N-alkylamino-heterocylic compounds for the treatment of migraine | CNR1, CNR2, KCNH1 | HTR2A 425/4885HTR2C 127/4885HTR2B 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.